Ponatinib 15/30 mg tablets play a vital role in targeted cancer therapy, particularly for chronic myeloid leukemia (CML) patients who possess resistant gene mutations. By inhibiting BCR-ABL tyrosine kinase mutations, including the difficult-to-treat T315I mutation, Ponatinib offers hope for those with limited treatment options. Ponatinib 15 / 30 mg in India, provides targeted action with improved outcomes. This innovative treatment is made accessible through Impomed Healthcare, supporting patients needing advanced cancer care solutions.